Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer

Phase 2

Terminated

• Conditions: Head and Neck Cancer
• Interventions: Drug: Erlotinib

• Registration Number: NCT00750555
• Lead Sponsor: Geisinger Clinic

Brief Summary

Phase II Study of Maintenance Tarceva (Erlotinib) in patients with locally advanced Head and Neck Cancer after treatment with curative intent

Detailed Description

Not available

Study Timeline

• Study Start: 2008-09
• Study First Submitted: 2008-09-09
• Study First Submitted QC: 2008-09-09
• Study First Posted: 2008-09-10
• Primary Completion: 2009-12
• Study Completion: 2009-12
• Results First Submitted: 2019-01-14
• Results First Submitted QC: 2019-01-14
• Status Verified: 2019-02
• Last Update Submitted: 2019-02-04
• Results First Posted: 2019-02-05
• Last Update Posted: 2019-02-26

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 4

Inclusion Criteria

• Stage III, IV SCCHN
• Completed curative treatment

Exclusion Criteria

• Prior chemotherapy or radiotherapy
• Recurrent disease

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
1	Erlotinib	-

Primary Outcome Measures

Name	Time	Method
One Year Disease Free	1 year	Per our current document retention policy, and the fact that the investigator, study staff, and record owner are no longer employed at our site, we do not have any collected data for pre-specified Primary and Secondary Outcome Measures to report in Outcome Measure data table.

Secondary Outcome Measures

Name	Time	Method
Overall Survival	2 years	Per our current document retention policy, and the fact that the investigator, study staff, and record owner are no longer employed at our site, we do not have any collected data for pre-specified Primary and Secondary Outcome Measures to report in Outcome Measure data tables.

Trial Locations

Locations (1)

Geisinger Health System; 🇺🇸 Danville, Pennsylvania, United States